Lobe Sciences Ltd.
LOBE
CNSX
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -100.00% | -100.00% | -84.18% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -100.00% | -100.00% | -84.18% | -- |
| Cost of Revenue | 107.35% | -931.09% | -931.09% | -983.89% | -- |
| Gross Profit | -101.27% | -77.45% | -77.45% | -57.74% | -- |
| SG&A Expenses | 1.71% | -23.57% | -29.22% | -38.92% | -25.88% |
| Depreciation & Amortization | -100.00% | -71.64% | -20.42% | 91.41% | 267.73% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.37% | -44.77% | -50.55% | -52.20% | 2.96% |
| Operating Income | -1.59% | 23.83% | 34.28% | 44.13% | 25.38% |
| Income Before Tax | -91.29% | -74.27% | -49.13% | 3.96% | 54.31% |
| Income Tax Expenses | -84.33% | -84.33% | -84.33% | -84.33% | -- |
| Earnings from Continuing Operations | -79.04% | -62.78% | -40.65% | 7.49% | 50.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.18% | -62.78% | -40.65% | 7.49% | 50.89% |
| EBIT | -1.59% | 23.83% | 34.28% | 44.13% | 25.38% |
| EBITDA | -3.59% | 23.57% | 35.33% | 45.92% | 28.07% |
| EPS Basic | -7.96% | -7.22% | -1.28% | 34.77% | 76.46% |
| Normalized Basic EPS | 35.59% | 38.46% | 38.03% | 42.53% | 74.73% |
| EPS Diluted | -7.96% | -7.22% | -1.28% | 34.77% | 76.46% |
| Normalized Diluted EPS | 35.59% | 38.46% | 38.03% | 42.53% | 74.73% |
| Average Basic Shares Outstanding | 67.91% | 49.70% | 25.49% | 5.54% | 43.61% |
| Average Diluted Shares Outstanding | 67.91% | 49.70% | 25.49% | 5.54% | 43.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |